NasdaqGM:GHRSPharmaceuticals
What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders
Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress.
An additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around...